Is Rydapt Used for Other Conditions?
Acute myeloid leukemia (AML) is one of two illnesses that Rydapt is used to treat in adults.
Mastocytosis, a disorder that affects mast cells, is the other condition Rydapt is used to treat. Mast cells are a type of white blood cells that typically assist your body in battling infections.
Your body produces an excess of mast cells if you have mastocytosis. Your body may develop a buildup of these cells. The production of healthy blood cells by your body may be hampered by this buildup. Mastocytosis has been linked in some cases to cancer.
Rydapt is specifically used to treat three types of adult mastocytosis:
- Aggressive systemic mastocytosis: The bone marrow and various organs, such as the liver and spleen, develop clusters of aberrant mast cells as a result of this type of mastocytosis.
- Systemic mastocytosis with associated hematologic neoplasm: A hematological malignancy causes systemic mastocytosis in this situation. (The phrase “hematologic neoplasm,” which broadly refers to blood malignancies.) Along with mast cells, different blood cell types are impacted by this disorder.
- Mast cells leukemia (MCL): People with aggressive systemic mastocytosis are at risk for developing MCL, a rare form of leukemia (a type of cancer). Mast cell levels rise in your blood and bone marrow when you have MCL.
Rydapt is a member of the class of medications known as kinase inhibitors [9]. Rydapt is a form of targeted therapy, as are other kinase inhibitors. These medications affect certain bodily objectives.
Rydapt works by reducing or stopping the body’s production of mast cells. It also hinders or halts their movement. The medication may also inhibit histamine, which can contribute to mastocytosis symptoms. Mast cells release a substance called histamine that can lead to inflammation. Its release may occur as a result of specific medical problems or an allergic reaction.